Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-4827 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Part A-Dose escalation and confirmation | EXPERIMENTAL | - |
| Part B - Prostate/Ovarian Cancer Cohort | EXPERIMENTAL | - |
| Part C - T-PLL/CLL cohort | EXPERIMENTAL | - |
| Part D - CRC, endometrial, breast, and ovarian cancer cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MK-4827 | DRUG | MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D). |
Inclusion criteria: * For Part A, participants must have a cytologically- or histologically-confirmed metastatic or locally advanced solid tumor for which standard therapy does not exist or the participants have refused standard therapy. * For Part B, participants must have a cytologically- or hist...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MK-4827 is an investigational small molecule being studied for the treatment of advanced solid tumors. It was evaluated in a Phase 1 clinical trial that also included patients with chronic lymphocytic leukemia and T-cell prolymphocytic leukemia. The drug is being developed by GSK plc.
MK-4827 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in clinical development for oncology indications.
MK-4827 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a controlled study that enrolled 113 participants. The drug is investigational and has not been approved by regulatory authorities.
MK-4827 has been studied in one completed clinical trial, identified as NCT00749502. This Phase 1 study evaluated the drug in participants with advanced solid tumors or hematologic malignancies, including chronic lymphocytic leukemia and T-cell prolymphocytic leukemia.
MK-4827 is the primary name used for this investigational drug. No alternative names have been reported for this asset in the available clinical trial information.